Hepatitis E vaccine

Abstract

Hepatitis E is an emerging disease in resource-poor regions of the world. It is estimated that about 2 billion people live in areas endemic for this disease. The inability to reproducibly culture hepatitis E virus makes it impossible to develop traditional live or inactivated vaccines. However, significant progress has been made in developing and testing recombinant subunit vaccines based on the viral capsid protein. This review summarizes these efforts.

Introduction

Hepatitis, or inflammation of the liver, can be due to one of several causes including viruses, drugs, toxins, autoimmune diseases, etc. Among infectious agents, at least five viruses are known to primarily affect the liver and cause hepatitis—hepatitis A, B, C, and E viruses and the delta agent, abbreviated as HAV, HBV, HCV, HEV, and HDV, respectively. While infection with HAV and HEV causes only an acute, self-limited disease, the other agents are known to persist for long periods in some of those infected, leading to chronic hepatitis. It is estimated (R.H. Purcell, personal communication (oral), July 2006) that of the 6 billion world population, the numbers of those who have been exposed to these viruses (and of those with chronic infection with each) are as follows: HAV, 5 billion (none); HBV, 4 billion (350 million); HCV, 200 million (170 million); HDV, 17 million (15 million), and HEV, 2 billion (none).

HEV causes hepatitis E, a disease transmitted predominantly through the fecal-oral route, primarily through contaminated drinking water [1]. Large waterborne outbreaks of hepatitis E have been recorded, besides rampant sporadic infections in endemic areas. Person-to-person transmission of HEV appears to be uncommon. The disease is clinically indistinguishable from hepatitis A. It generally has a low case mortality [1]; however, a peculiar feature of hepatitis E is its high mortality among pregnant women, reaching up to 20–30% [2].

The epidemiology of hepatitis E is more complex than was initially appreciated, and many features remain unexplained. The age-related seroprevalence of anti-HEV antibodies shows three different patterns. In endemic areas such as Asia, the Middle East, and North Africa, anti-HEV seroprevalence increases with age up to 30–40% in adults, whereas more than 95% of people older than 5 years living in these regions have anti-HAV antibodies [3]. Since both HEV and HAV are transmitted by the fecal-oral route and are endemic to the same regions, the reasons for this difference are not clear. However, the relatively low frequency of anti-HEV antibodies among adults possibly explains why hepatitis E is prevalent in young adults living in these regions. Another pattern has been observed in Egypt wherein anti-HEV is common in young children with seroprevalence rates reaching up to 70% by the third decade of life [4]. In these regions, hepatitis E epidemics are uncommon, though sporadic cases do occur. In developed countries of western Europe and the United States, hepatitis E is rare, and most cases are related to travel to HEV-endemic areas. However, surprisingly, relatively high rates of anti-HEV positivity were observed in US blood donors in comparison with those expected from the low disease rates. A possible explanation might be exposure to related animal viruses, for example, swine HEV, in these countries [5].

The HEV genome was first cloned and sequenced in the early 1990s from a Burmese isolate [6]. Subsequently, several isolates from other geographic regions have also been sequenced [7–11]. The HEV genome (Fig. 1) contains three open-reading frames (ORFs) that encode the ORF1 nonstructural polyprotein with proposed biochemical functions, the ORF2 major viral capsid protein, and the ORF3 regulatory protein [12]. Currently, HEV is classified into the family Hepeviridae and genus Hepevirus [13]. Based on the available nucleotide sequences, HEV isolates have been divided into five genotypes, each with a different geographical distribution. Of these, genotype 1 includes most human isolates from Asia and genotype 2 includes a solitary divergent human isolate from Mexico. Genotype 3 includes human and animal isolates from the United States, western Europe, Japan, Korea, Taiwan, Spain, and Argentina. Genotype 4 also includes human and animal isolates from China, Japan, Taiwan, and Vietnam, as well as swine (but not human) isolates from India. Genotype 5 includes the avian hepatitis E virus (AHEV), which has been described in chicken and turkeys, and shows about 50% nucleotide similarity to the human and swine HEV isolates. While the serotype status of AHEV is not fully understood, all human and mammalian HEV isolates belonging to genotypes 1–4 display a single serotype. This bodes well for the development of hepatitis E vaccines.

Fig. 1.

The genome organization of HEV. The HEV genome is an ∼7.2-kilobase (kb) single-stranded (+) sense RNA that encodes three open-reading frames: ORF1, ORF2, and ORF3. The ORF1 encodes the nonstructural polyprotein that contains various functional domains (methyltransferase, MeT; protease, Pr; RNA helicase, Hel; RNA-dependent RNA polymerase, RdRp). The ORF2 encodes the viral capsid protein and ORF3, a protein with regulatory properties. The 660-amino acid ORF2 protein has an N-terminal signal sequence (SS) and three putative domains (S. Jameel, 2008). Of these, domain 1 (∼100 residues) with a high density of arginine residues is likely to be involved in RNA encapsidation. Domain 2 (∼240 residues) is predicted to form the core of the viral capsid and domain 3 (∼300 residues) is predicted to be exposed on the virus particle. A neutralization epitope (amino acids 458–607) was localized to domain 3 and is likely to be involved in the binding of HEV to its cellular receptor

All hepatitis E vaccine efforts have so far focused on the ORF2 capsid protein of the virus (Fig. 1). Since the virus does not grow reliably to high titers in cell culture, traditional live attenuated or killed viral vaccine approaches have been ruled out. Various recombinant forms of the ORF2 protein, expressed using different heterologous systems, are being explored [14]. Recently, a few studies have also explored the use of ORF2-expressing naked DNA constructs. The details of these approaches are presented below.

The immunologic basis for an HEV vaccine

In spite of some contradictory observations, several lines of evidence suggest that recombinant subunit vaccines for hepatitis E might be feasible. Natural infections in humans, as also experimentally transmitted infections with HEV in the primate models, are associated with the development of serum antibodies to HEV [15]. Rechallenge with HEV-containing inocula in animals with prior experimental HEV infection usually does not lead to reinfection, at least for a period of several months following the initial infection; however, anecdotal accounts of successful experimental infection of macaques in the presence of preexisting anti-HEV antibodies are available. Epidemiologic observations during a hepatitis E outbreak suggest that people previously infected with HEV are protected during epidemics of the disease [16]. This is in agreement with the high attack rates observed among young adults. The duration of a protective antibody response following HEV infection, however, remains unresolved. While some studies have noted the disappearance of IgG anti-HEV within 6–12 months [17] or 1–4 years [17, 18], at least one study has reported the persistence of IgG anti-HEV for up to 14 years in about half of the people infected during an outbreak of hepatitis E [19]. It has been possible to protect macaques against experimental transmission of HEV by administering high-titer immune serum globulin [15]. However, pooled normal human immune plasma from an endemic area showed no protection in clinical trials, though this may have been related to the relatively low dose of the immunoglobulin used and the relatively low levels of anti-HEV in the unselected pooled plasma [20, 21]. Similarly, anti-HEV-positive serum derived from a human volunteer with a history of hepatitis E 4 years ago did not protect macaques from experimental transmission of HEV [22]. Although at least four genotypes of HEV have been reported to exist globally [12, 23], these represent a single serotype of the virus [23, 24] and raise optimism that antibodies to one strain will protect against all others. Finally, antibodies to the ORF2 capsid protein of HEV were also found to neutralize the virus in vitro [25].

Together, these observations suggest that it may be possible to induce protective immunity against HEV infection by raising broadly reactive antibody responses to the ORF2 capsid protein. However, it appears that successful immunization will need to achieve higher and longer lasting antibody titers than those achievable in a natural infection.

Recombinant protein vaccines

Several recombinant ORF2 antigens of different lengths have been expressed using a variety of expression systems and have been shown to induce anti-ORF2 antibody responses (Table 1). While many truncated versions of the ORF2 protein have been expressed, purified, and tested for immunogenicity and efficacy, the size and nature of the native protein in HEV virions remains elusive. Five of these antigens (TrpE-C2, pE2, Pakistan 56 kDa, Burma 62 kDa, and Burma 50 kDa) have also been shown to produce neutralizing antibody responses (Table 1), and are therefore relevant to the discussion here as potential candidate vaccine antigens.

Table 1.

HEV candidate vaccines

HEV (source)	Name	ORF2 amino acids (range)	Reference	Remarks
Proteins expressed in Escherichia coli
China	ORF2	1–660	[26]	Neutralizing Ab
Burma	TrpE-C2	221–660	[27]
China	ORF2.1	394–660	[28]
China	pE2	394–604	[29]	Preclinical efficacy
Mexico, Burma	3.2	612–654	[30]
Proteins expressed in insect cells
Burma	72 kDa	1–660	[31]
Pakistan	63 kDa	112–660	[32]
	56 kDa	112–607	[33]	Preclinical efficacy; human clinical trials
	53 kDa	112–578		VLPs; neutralizing Ab
Burma	62 kDa	112–636	[31]	Neutralizing Ab
	50 kDa	112–534	[34]	VLPs; preclinical efficacy
Proteins expressed in other systems
China	HBV/HEV	551–607	[35]	In yeast Pichia pastoris
	HEV-E2	394–604	[36]	In transgenic tomato
Naked DNA
Burma	pJHEV	1–660	[37]
India	pcDNA-ORF2	1–660	[38]
Burma	pcHEVORF2	1–660	[39]	Preclinical efficacy
DNA plus protein
India	pcDNA-NE	458–607	[40]
	+26 kDa		[41]	Preclinical efficacy

Proteins expressed in Escherichia coli

Only two of the proteins expressed in E. coli have shown promise as vaccine candidates, the rest being useful as diagnostic reagents. The first of these, TrpE-C2, contained a 221- to 660-amino acid carboxy-terminal fragment of the ORF2 protein of a Burmese strain (genotype 1) of HEV fused to tryptophan synthetase [27]. In preclinical challenge experiments, two cynomolgus macaques vaccinated with the recombinant TrpE-C2 protein were challenged with wild-type homologous (genotype 1) or heterologous (genotype 2) HEV. The animal receiving homologous challenge showed no evidence of HEV infection. However, the animal challenged with a heterologous Mexican strain of HEV did get infected as demonstrated by viremia, viral excretion, and increase in anti-HEV antibody levels, but did not develop biochemical or histological evidence of hepatitis.

Another candidate, pE2, was expressed as a glutathione-S-transferase (GST) fusion protein containing amino acids 394–660 of the ORF2 protein from a Chinese isolate [29]. Following its purification and cleavage from the GST partner, the pE2 polypeptide was found to self-associate into a dimer. The dimeric form of the protein was efficiently recognized by convalescent human sera from patients with hepatitis E, and antibodies to it successfully recognized HEV in an immune capture assay [29]. Cynomolgus macaques vaccinated with pE2, but not control animals, showed efficient seroconversion and no infection following challenge with the homologous virus [42]. Another candidate vaccine expressed in bacteria, called HEV239, contains ORF2 amino acids 376–606 [43]. This consists of 23-nm particles that dissociate under mild denaturing conditions into homodimers [44] that react strongly with acute and convalescent sera of hepatitis E patients [43–45] and HEV-specific monoclonal antibodies [29]. In primate studies, this vaccine was found to give protection against HEV genotypes 1 and 4, and sera from vaccinated animals neutralized infectivity of HEV in vitro [43]. There are reports of human safety and efficacy trials of this vaccine, but no published results are yet available.

Proteins expressed in insect cells

The recombinant ORF2 proteins produced using baculovirus vectors in insect cells have been pursued vigorously as candidate vaccines. In this system, the 72-kDa ORF2 protein of a Pakistani HEV strain (SAR55) is rapidly processed into smaller proteins of 63, 56, and 53 kDa. Of these, the 56-kDa form accumulates in the cytoplasm of insect cells, whereas the 53-kDa form is secreted as virus-like particles (VLPs) [32]. The recombinant 56-kDa ORF2 protein was found to be an efficient immunogen in monkeys when given with an alum adjuvant [15, 46]. Furthermore, the vaccinated animals were protected from intravenous challenges with high doses of both homologous and heterologous strains of HEV [15, 46]. This candidate vaccine has moved further into preclinical development and human clinical trials [14].

A 62-kDa recombinant ORF2 protein from a Burmese HEV strain produced in insect cells has also been tested in monkeys [47]. Two 20 μg doses of an alum-adjuvanted preparation were shown to protect cynomolgus macaques against challenge by a heterologous HEV strain.

Similarly, insect cells expressing the ORF2 protein of the Burmese strain of HEV secreted VLPs made up of a 50-kDa protein [34]. Whether this protein and the 53-kDa secreted protein produced from insect cells expressing the SAR55 ORF2 protein are identical has not been determined. These VLPs, which are 24 nm in size, have been structurally characterized using cryoelectron microscopy [48] and have been found to induce both systemic and mucosal anti-HEV responses when administered orally to mice [49]. Cynomolgous macaques orally vaccinated with these VLPs, without any added adjuvant, have recently been shown to raise systemic and mucosal anti-HEV antibody responses [35]. Furthermore, these animals were fully protected against infection and hepatitis following an intravenous challenge with HEV [35]. These results raise the possibility of developing an oral recombinant hepatitis E vaccine. The HEV ORF2 VLPs have also been tested as an oral vaccine vehicle for presenting foreign epitopes [50] and to orally deliver encapsulated DNA to mucosal sites [51].

All the baculovirus-mediated ORF2 protein expression and purification have been carried out in either Sf21 or Tn5 insect cell lines. We have also explored the use of intact Spodoptera litura larvae for this purpose [52]. A recombinant baculovirus was engineered to express a truncated ORF2 antigen from an Indian strain of HEV. This contained amino acids 112–660 with an inframe deletion of a hydrophobic region between residues 585 and 610. High levels of the recombinant ORF2 antigen were expressed and found to accumulate in the larval fat bodies within 5 days of virus injection into fourth-instar S. litura larvae. The recombinant protein could be purified to homogeneity in an estimated yield of 0.2 mg per larva [52]. This exemplified the use of insect larvae as bioreactors, a potentially economical method for recombinant protein expression.

Proteins expressed in other systems

A C-terminal peptide of ORF2 encompassing amino acids 551–607 has been expressed on chimeric VLPs formed by the hepatitis B surface antigen (HBsAg) in the methylotropic yeast Pichia pastoris [53]. The VLPs showed reactivity to human sera containing antibodies against HBV as well as those with anti-HEV antibodies, and are being explored as a recombinant HBV/HEV bivalent vaccine candidate. In more recent studies, ORF2 antigens 69–660 and 112–660 have been expressed independently in P. pastoris, and the purified proteins have been shown to induce high titer antibodies in rhesus monkeys [54].

The 23-kDa ORF2 antigen (pE2; residues 394–604), earlier expressed in bacteria [29], has recently been expressed in transgenic tomato plants [36]. The expression levels of the protein in this system were, however, quite low, being in the range of 40–60 ng/g of the leaf or fruit tissue [36].

DNA vaccines

Direct injection of plasmid DNA has been shown to cause intracellular synthesis of immunizing viral antigens, as well as induction of humoral and cellular immune responses. Vaccination with HEV ORF2 expression constructs has been shown to elicit anti-HEV antibodies [37, 38] and immunologic memory [55] in mice. These antibody responses can be augmented by codelivery of genes for the immunomodulatory cytokines interleukin 2 and granulocyte-macrophage colony stimulating factor [38]. In a preclinical efficacy experiment, cynomolgous macaques vaccinated with an ORF2 expression construct were protected from virus challenge only when the DNA was administered with a gene gun and not when it was given as an intradermal injection [39]. A DNA prime plus recombinant protein boost was recently shown to be immunogenic in mice [39]. This report utilized both DNA and recombinant protein representing the HEV ORF2 neutralizing epitope. An approach based on injection of a liposome carrying this DNA vaccine and a recombinant protein antigen was also reported to afford protection against virus challenge in rhesus macaques [41]. Although DNA vaccines have obvious advantages of stability and ease of preparation, much work remains on the mode of delivery and characterization of immune responses.

Neutralization epitopes and assay systems

Several ORF2 antigens have been shown to be immunogenic as well as to induce antibodies that recognize divergent strains of HEV. The important parameter for vaccine development is to ascertain whether these are capable of neutralizing both homologous and heterologous viral strains.

One neutralizing epitope has been identified between amino acids 578 and 607 of the ORF2 protein. It was observed that two neutralizing monoclonal antibodies selected by phage display binding to the ORF2 112–607 protein, but not to the ORF2 112–578 protein [56]. Antibodies to purified ORF2 proteins prepared in rabbits or guinea pigs are not as effective as antibodies found in convalescent human or macaque sera following infection, for in vitro neutralization of homologous or heterologous HEV strains. Shorter fragments of the ORF2 protein react more readily with antibodies in human sera than the full-length protein [34, 57], suggesting that the neutralization (and immunodominant) epitopes may be masked in the longer proteins. These observations also emphasize that the tertiary structure of the protein used for vaccination is likely to be crucial.

An enzyme-linked immunosorbent assay (ELISA) for putative neutralizing antibodies to HEV has been developed that detects antibodies to all four genotypes of the virus [58]. This test has been used with sera from experimentally inoculated macaques, but remains to be evaluated in a human field situation. An ELISA based on truncated forms of the ORF2 protein has also been developed to differentiate between vaccination and infection (S. Emerson, personal communication (oral), May 2007). At this time, vaccination of cynomolgous or rhesus macaques, and their subsequent challenge with homologous and heterologous HEV strains, appears to be the best model for assaying the potential efficacy of a candidate vaccine. The in vitro assays for neutralizing antibodies against HEV and the full-length infectious clones of HEV [59, 60] may, in future, provide tools for quicker and easier assessment of protective efficacy of the induced antibodies.

Clinical trials

Preclinical immunogenicity and efficacy studies in humans have been conducted on only a limited number of HEV vaccine candidates. Of these, only 1 vaccine has so far progressed into human clinical trials. The 56-kDa baculovirus-expressed ORF2 protein developed at the National Institutes of Health, Bethesda, MD, was licensed to Glaxo SmithKline and was evaluated in humans by the Walter Reed Armed Forces Institute of Medical Sciences, Washington, DC [14]. Studies in rhesus macaques have shown this preparation to be highly immunogenic and efficacious in preventing infection following intravenous challenge with three different genotypes of HEV [61]. In phase I trials in healthy volunteers in the United States and Nepal, the vaccine proved to be safe and immunogenic [14, 62]. A 3-dose immunization schedule with 1, 5, 20, or 40 μg of the recombinant protein gave progressively better titers with higher doses. With three doses of 40 μg each, immunologic memory recall with geometric mean titers of about 75 WHO units/ml were attained [62].

Recently, the results of a phase II–III efficacy trial of this vaccine, which was carried out in Nepal, have been published [63]. The study included 2,000 volunteers from the Nepalese Army who tested negative for anti-HEV antibodies. They were randomized to receive 20 μg of either the alum-adjuvanted recombinant HEV protein or a matched placebo, each given as three doses at 0, 1, and 6 months, and followed up for 2 years postvaccination. Overall, 88% of volunteers completed the study with median follow-up duration of 804 days. Among those who had received all three doses of the vaccine as scheduled, the rate of clinically overt (symptomatic) acute hepatitis E was markedly lower than those who received a matching placebo, with an impressive vaccine efficacy rate of 95%. A somewhat lower efficacy rate of 85.7% was observed in the period between 14 days after dose 2 until dose 3. Adverse effects of the vaccine were no different from those observed with the placebo, except for an increased injection-site pain. However, the study had some limitations. First, the study subjects were overwhelmingly (>99%) men and were mostly young (mean age = 25 years). Second, the authors did not study the HEV infection rate, focusing instead on clinical disease rate. And finally, by the end of the study, anti-HEV antibody titers had declined significantly so that nearly 44% of subjects had antibody titers below the level considered as protective.

Conclusions

Depending on the preclinical efficacy data and results of the clinical trial published only recently, the hepatitis E vaccine based on recombinant HEV ORF2 protein shows clear evidence of protection against occurrence of symptomatic hepatitis E. Although these results are very encouraging, several questions still remain to be answered. First, how long does the vaccine-mediated protection last? Can long-term immunity to hepatitis E be achieved through vaccination when it appears to wane off following natural infection? Second, it remains to be seen whether the vaccine offers protection only against symptomatic disease or also against HEV infection. In the former case, the vaccine would not be expected to make a major dent in the epidemiology of HEV infection in the endemic regions. However, several vaccines currently in use do not offer sterilizing immunity. In some clinical situations, protection from disease and the ensuing liver damage, especially the onset of fulminant hepatic failure, may be a desirable goal. In such situations, the vaccine may still be useful despite its failure to prevent the infection. Third, it is not clear whether the vaccine would be useful for postexposure prophylaxis. This is particularly important if the vaccine is to be used for controlling an HEV outbreak, wherein exposure to the infection has already occurred, possibly several days before the identification of the outbreak.

Who should get the vaccine? A vaccine, even one with short-term efficacy, is likely to benefit risk groups such as travelers to endemic areas and pregnant women living in endemic areas. Persons with underlying chronic liver disease are also at an increased risk of developing severe complications following HEV infection [64] and would be a large target group, especially in hepatitis E endemic regions. However, it will be important to test that the vaccine retains its efficacy in such groups.

While the development of an HEV vaccine is a welcome step, its dissemination remains an unexplored area. Experience in resource-poor countries, where hepatitis E is endemic, has shown that hepatitis B vaccine is not readily available to the population at risk even decades after its introduction. The vaccine cost, the cost of delivering it, and maintaining a cold chain will remain critical issues with the hepatitis E vaccine as with several others. Thus, while “proof of principle” for hepatitis E vaccination has been delivered, there are still several challenges that need to be overcome in future before the morbidity and mortality associated with HEV infection can be tackled successfully.